The Development of Lipid-Based Sorafenib Granules to Enhance the Oral Absorption of Sorafenib

Simple item page
dc.creatorMans, Jaylen C.
dc.creatorDong, Xiaowei
dc.creator.orcid0000-0002-2266-7952 (Dong, Xioawei)
dc.creator.orcid0000-0003-1150-1647 (Mans, Jaylen C.)
dc.date.accessioned2024-01-03T20:27:18Z
dc.date.available2024-01-03T20:27:18Z
dc.date.issued2023-12-23
dc.description.abstractSorafenib (SFN) is an anticancer multi-kinase inhibitor with great therapeutic potential. However, SFN has low aqueous solubility, which limits its oral absorption. Lipids and surfactants have the potential to improve the solubility of water-insoluble drugs. The aim of this study is thus to develop novel lipid-based SFN granules that can improve the oral absorption of SFN. SFN powder was coated with a stable binary lipid mixture and then absorbed on Aeroperl 300 to form dry SFN granules with 10% drug loading. SFN granules were stable at room temperature for at least three months. Compared to SFN powder, SFN granules significantly increased SFN release in simulated gastric fluid and simulated intestinal fluid with pancreatin. Pharmacokinetics and tissue distribution of SFN granules and SFN powder were measured following oral administration to Sprague Dawley rats. SFN granules significantly increased SFN absorption compared to SFN powder. Overall, the lipid-based SFN granules provide a promising approach to enhancing the oral absorption of SFN.
dc.description.sponsorshipResearch reported in this publication was supported by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number R35GM138225 to Dong, X.
dc.identifier.citationMans, J. C., & Dong, X. (2023). The Development of Lipid-Based Sorafenib Granules to Enhance the Oral Absorption of Sorafenib. Pharmaceutics, 15(12), 2691. https://doi.org/10.3390/pharmaceutics15122691
dc.identifier.issn1999-4923
dc.identifier.issue12
dc.identifier.urihttps://hdl.handle.net/20.500.12503/32451
dc.identifier.volume15
dc.publisherMDPI
dc.relation.urihttps://doi.org/10.3390/pharmaceutics15122691
dc.rights.holder© 2023 by the authors.
dc.rights.licenseAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourcePharmaceutics
dc.subjectanticancer
dc.subjectbioavailability enhancement
dc.subjectlipid-based formulations
dc.subjectoral formulation
dc.subjectpoorly water-soluble drug
dc.titleThe Development of Lipid-Based Sorafenib Granules to Enhance the Oral Absorption of Sorafenib
dc.typeArticle
dc.type.materialtext

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
10.3390_pharmaceutics15122691.pdf
Size:
3.73 MB
Format:
Adobe Portable Document Format
Description:
full text article
Download

Collections

Publications -- Xiaowei Dong